Zanubrutinib as Third-Line and Beyond Therapy for FL
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
Practical guidance for institutions navigating bispecific therapy integration without prior experience is provided.
Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.
Discover the latest advancements in cardiology robotics, technology, and procedures in four recently approved innovations.
Considerations for enhancing bispecific drug effectiveness through strategic EMR utilization in healthcare are explored.